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Clear Reception
Elucidating the Binding Characteristics of
Bisphenol A
Several studies have indicated that bisphenol A (BPA), which is
widely used in polycarbonate plastic and epoxy resin manufactur-
ing, can disrupt normal endocrine function. Given that BPA’s
estrogen receptor (ER) binding and interaction are 100–1,000
times weaker than those of endogenous hormones, researchers have
hypothesized that BPA interacts with nuclear receptors other than
ER. A recent study directly assayed BPA’s interaction with estrogen-
related receptor-γ (ERR-γ), one of a family of “orphan” nuclear
receptors—those for which natural ligands are unknown—and
clarified the structural requirements that enable BPA to bind this
receptor [EHP 116:32–38; Okada et al.].
Earlier research by the same team demonstrated that BPA
strongly binds ERR-γ. The research also showed that BPA preserves
ERR-γ’s high constitutive activity. Receptors with constitutive
activity trigger molecular events in the absence of a ligand; specific
ligands known as inverse agonists can deactivate these receptors. 
The authors emphasize the importance of this investigation by
noting that ERR-γ is very strongly expressed in the mammalian
brain during development and in the brain, lung, and other tissues
in adults; unpublished results from this group show the highest
expression in the placenta. It is possible that BPA’s binding ERR-γ
could affect the receptor’s role by activating transcription at the
wrong times.
Using tritium-labeled BPA, the researchers conducted the first
saturation binding assay to precisely characterize how strongly BPA
binds ERR-γ. They also ran competitive binding assays with BPA
analogs and other industrial chemicals, including phenol deriva-
tives, to identify which structural characteristics of the chemicals
are critical for binding ERR-γ and maintaining its constitutive
activity. They found specific, extremely high binding affinity of
BPA for ERR-γ. BPA analogs varied in their ability to bind the
receptor, and phenol derivatives were newly discovered to be
potential candidates for ERR-γ–mediated endocrine disruption.
These findings raise the immediate question of whether report-
ed BPA-related endocrine disruption might actually be mediated
through ERR-γ rather than through ER. Additionally, the
researchers stress the need to determine the normal physiologic
roles of ERR-γ as well as the ways in which BPA might affect these
roles. Given the strong expression of ERR-γ in the fetal brain and
placenta, further information is especially urgent with regard to
outcomes for newborns. –Julia R. Barrett
Mitigating Methylmercury
Exposure
Study Confirms Potential of NAC as Antidote
and Biomarker 
Researchers have been searching for better ways to quantify and mitigate
exposures to the neurotoxicant methylmercury (MeHg). Results from a
new animal study confirm that N-acetylcysteine (NAC), already used to
treat acetaminophen overdose, may serve as a quick-acting antidote for
and biomarker of MeHg exposure [EHP 116:26–31; Aremu et al.].
MeHg is created when elemental mercury released through the
burning of coal, waste incineration, and other industrial processes is
metabolized by aquatic microorganisms such as anaerobic bacteria. It
bioaccumulates rapidly, with concentrations in some top marine preda-
tors reaching 100,000 times that of surrounding seawater. Fish con-
sumption is the major source of human exposure. MeHg can cause
irreversible brain damage, and the
developing brain is especially vulnera-
ble to its effects. 
Treatments to mitigate MeHg
exposure involve chelation, the
administration of compounds that
bind mercury, speeding its elimina-
tion from the body and thereby mini-
mizing its toxicity. Current chelation
methods can be nonspecific, depleting
not only MeHg but also minerals
required for normal cell function,
such as calcium. 
In contrast, chelation treatment
with NAC does not affect levels of
essential minerals. NAC, a derivative
of the amino acid L-cysteine and a pre-
cursor of the antioxidant glutathione,
is itself a potent antioxidant. NAC can
be delivered intravenously or orally. 
In the current study, adult rats were injected with NAC
(1 mmol/kg) 2 hours after being exposed to MeHg (0.1 µmol/kg).
The treated animals excreted about 5% of their body burden of
MeHg within 2 hours, compared with less than 0.1% excreted by
untreated animals. The response was transient and dose dependent,
with larger doses of NAC resulting in higher rates of MeHg excretion. 
These effects were not seen in preweaned rats (age 15–19 days)
treated with NAC. The researchers speculate that the transporter sys-
tems needed to move the MeHg–NAC complex through the kidney
do not mature until animals reach adulthood (around 30 days of age).
However, oral NAC treatment in pregnant rats (10 mg/mL in drink-
ing water) did protect their fetuses, reducing concentrations in the
placenta and the whole fetus by 70–90%. In the dams themselves,
NAC also reduced MeHg concentrations by 70–90% in the brain, by
about 20% in the kidney, and by 60–80% in the blood and liver.  
NAC’s short half-life, about 2 hours, may allow it to serve as an
accurate real-time biomarker of MeHg exposure. According to the
researchers, such a quick-acting biomarker could provide critical
early warning of possible acute expo-
sures, where early treatment is criti-
cal to prevent neurological damage.
In the current study, MeHg excre-
tion in animals treated with NAC
was proportionate to MeHg body
burden at the time of treatment. In
contrast, standard monitoring tech-
niques, which use hair analysis, can
provide only a history of exposure
and cannot guide immediate treat-
ment for acute exposures. The
researchers propose that future stud-
ies test NAC in adult humans as a
biomarker of exposure  and a possi-
ble treatment for MeHg exposure,
especially for pregnant women
whose unborn children are in dan-
ger of prenatal MeHg exposure.
–Kris Freeman NAC offers promise as an antidote to acute MeHg exposureScience Selections
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Science in the Courtroom
Examining Standards for Litigation-Based Research
Over the last 20 years, the term “junk science” has gained increasing
use by defendants in toxic tort litigation as a pejorative phrase to
discredit health effects data that do not meet some standard for sci-
entific validity—or, some say, that are favorable to the interests of
plaintiffs. Proponents of tort reform have argued that many large
jury verdicts are the unjustified products of questionable scientific
data presented by plaintiff lawyers to easily swayed jurors. Courts
have responded by raising the bar that scientific evidence must
exceed in order to be admitted as evidence. But has this change pro-
duced sound results? Is there really a distinction between litigation-
based science and other science? In a mini-monograph in this issue,
5 articles examine these questions and others that arise when exam-
ining the juncture of science and litigation [EHP 116:116–147].  
Acknowledging that conflicts of interest are an inherent compo-
nent of science-based litigation, authors Ronald L. Melnick, Kristina
A. Thayer, and John R. Bucher of the NIEHS conclude that public
health decisions to allow exposure to possible carcinogens should not
rely “on untested hypotheses that are promoted to explain away
adverse outcomes.” Their article focuses specifically on rodent car-
cinogenicity studies and examines how strict attention to design and
evaluation can reduce inaccurate conclusions and provide data that
are useful for evaluating human
health risks.
The authors cite early animal
studies on benzene as an example
of poor design that failed to detect
carcinogenic effects, even though
epidemiologic studies demonstrat-
ed a causal association between
benzene exposure and leukemia in
humans. Those early studies
employed too few animals, insuffi-
cient controls, too short a study
duration, and inadequate levels of
exposure. In addition, the authors
write, “evaluations that are based
on incomplete necropsy or
histopathology, do not combine
related tumor effects, fail to adjust
for differences in animal survival,
or incorrectly use historical con-
trol data would not be expected to
produce reliable information on
chemical carcinogenesis.”
Courts, meanwhile, have also
taken steps to reduce the likeli-
hood of “junk science” influencing juries. Two of the articles in the
mini-monograph, the first by Leslie I. Boden and David Ozonoff
of the Boston University School of Public Health and the other by
Sheila Jasanoff of Harvard University’s Kennedy School of
Government, examine the assertion that science conducted to sup-
port litigation must be held to tougher admissibility standards than
other science. Appeals Court Judge Alex Kosinski made this claim
in 1995 in response to the Supreme Court remand in Daubert v.
Merrell-Dow Pharmaceuticals, Inc., deciding that judges were
henceforth required to assume roles as gatekeepers with the respon-
sibility of culling out unreliable expert evidence. As the authors
describe, many courts following Daubert have held that research
conducted specifically for the purpose of a litigation is inherently
less reliable than other science.
Boden and Ozonoff re-examine whether litigation-based science
should be treated differently from other science offered as evidence in
the courtroom. They conclude that it shouldn’t. Their contentions
include an assertion that cross-examination by attorneys aided by
competent experts, not just journal peer review, also serves the ends of
justice. They further argue that any science is subject to a variety of
biases; for example, they write, studies funded by pharmaceutical
companies or investments by corporations in research agendas tend to
favor their own economic interest. Finally, the authors argue that
tougher standards for litigation-generated science unfairly burden
plaintiffs.
In her article, Jasanoff agrees that restrictions placed on litigation-
based science following Daubert are misconceived because the scien-
tific knowledge needed to resolve legal disputes often arises only in
response to litigation. Rather than assign judges the role of gatekeep-
er, a more sensible approach, she writes, would be for judges to
assume the position of referee. In this role, judges would “focus on
the process through which litigation science is generated rather than
on its validity or invalidity. They would be in a position to structure
agreements among the parties that would be most conducive to pro-
ducing relevant and reliable knowledge.”
In a fourth article, Carol J. Henry and James W. Conrad, Jr., of
the American Chemistry Council focus on the role of federal agencies
rather than that of the courts. They write that the quality of agency
scientific research and testing is already subject to a variety of stan-
dards and practices (e.g., the
Federal Information Quality Act,
and peer review and transparency
in research practices), and argue
that these standards and practices
allow agencies to judge the quality
of work regardless of the reason
for which it was created. They also
point out that federal agencies are
required to accept and fairly con-
sider information provided by any
interested person in the course of
decision making. 
In the last paper, William R.
Freudenburg of the University of
California, Santa Barbara, takes a
critical look at the nature of bias
itself, concluding that scientists
oftentimes are not conscious of its
influence on them. Drawing from
personal experience, Freudenburg
describes litigation-based research
he conducted for a company that
never tried to censor his work and
consistently praised him for being
principled and credible. But he subsequently came to realize that
praise for his objectivity actually encouraged him to interpret his find-
ings in ways that would favor his corporate sponsors more than if they
had tried to tell him what to say. The problem, he writes, was “the
temptation to start changing my own judgments . . . in response to
their repeated insistence that it was precisely my independent and sci-
entific credibility that they valued.” 
The articles in the mini-monograph share a common thread:
when science is used to serve the purposes of litigation or administra-
tive proceedings, great care is needed to ensure its proper deployment,
and a courtroom judge is probably not the appropriate person to
decide on the reliability and relevance of scientific evidence.
Furthermore, the perception that bias is inherently bad or avoidable
may itself be biased. –Richard C. Dahl
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Should research conducted expressly for court use be held to
higher standards than any other research?